Recently, Kossel Medtech (Suzhou) Co., LTD. (hereinafter referred to as Kossel) which focuses on manufacturing PTCA balloon dilatation catheter stent, etc. Class 3 interventional cardiovascular medical devices in Su zhou China. Successfully completed the financing of over 100 million Yuan. This round of financing by Suzhou Juming Investment and Yueyin Medical Foundation lead investment, follow investors by Lingchuang Future.
This round of financing will help Kossel to enrich the peripheral product pipeline, build one-stop treatment product system in the peripheral intervention field, expand the production base, and attract more and more excellent high-end talents
Kossel was founded in November 2013, which is a platform enterprise with comprehensive production and research and development capabilities of vascular interventional devices, and is committed to providing clinical system solutions. Kossel is a national high-tech enterprise, with nearly 10,000 square meters of R & D and production base, a professional R & D and testing laboratory, with systematic independent innovation R & D capabilities and leading production and manufacturing capabilities, has nearly 100 intellectual property rights.
Kossel’s innovative product in the field of peripheral medicine, vena cava filter, has been successfully registered and commercialized. It is the first umbrella long-acting filter approved for registration in China, and several other innovative products will soon enter clinical trials. The balloon products in the field of coronary artery have obtained NMPA (China), FDA (United States), CE (European Union), PMDA (Japan), KFDA (Korea), and other multinational registration certificates and entered the international mainstream market.
Hu Qing, CEO of Kossel Medtech, said that kossel will never forget its original aspiration, keep in mind the mission of “developing excellent products, serving human health and benefiting more patients”, adhere to “cooperation and sharing”, continue to serve clinical practice and make contributions to the development of China’s medical device industry. This round of financing will also help Kossel faster and better development!
1